When innovation goes fast. The case of hemophilia
- 1 April 2019
- journal article
- research article
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 45, 95-101
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia ANew England Journal of Medicine, 2016
- Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia ANew England Journal of Medicine, 2016
- A first-in-human phase 1 study of ACE910, a novel factor VIII–mimetic bispecific antibody, in healthy subjectsBlood, 2016
- Factor VIIIa A2 Subunit Shows a High Affinity Interaction with Factor IXaJournal of Biological Chemistry, 2013
- The principal results of the International Immune Tolerance Study: a randomized dose comparisonBlood, 2012
- Factor VIII Light Chain Contains a Binding Site for Factor X That Contributes to the Catalytic Efficiency of Factor XaseBiochemistry, 2012
- The Factor VIIIa C2 Domain (Residues 2228–2240) Interacts with the Factor IXa Gla Domain in the Factor Xase ComplexJournal of Biological Chemistry, 2009
- The Hemophilias — From Royal Genes to Gene TherapyNew England Journal of Medicine, 2001
- Localization of a Factor X Interactive Site in the A1 Subunit of Factor VIIIaJournal of Biological Chemistry, 1997
- Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia ANew England Journal of Medicine, 1990